Labopharm Inc.

Labopharm specialized in reformulating existing small molecule drugs to improve their performance using proprietary drug delivery platforms. Its lead product was a once-daily tramadol formulation for pain, commercialized globally. OLEPTRO™, a novel trazodone formulation for depression, received US approval but faced commercialization challenges. The company entered a joint venture with Angelini to market OLEPTRO™ in the US but later undertook workforce reductions and strategic reviews due to financial pressures. As of the latest updates from early/mid‑2010s, Labopharm was not actively developing new programs or expanding commercialization efforts.